Sjögren's syndrome (SS) is a rare chronic and systemic autoimmune disorder, primarily characterized by lymphocytic infiltrations and autoimmune exocrinopathy and epithelitis as well as a female predominance (9:1 female-to-male predisposition ratio primarily in perimenopausal women) (1). The characteristic lymphocytic infiltration consists of activated T and B lymphocytes that affect exocrine glands and autoantibody production. SS occurs in 0.5-1% of the population, and the spectrum of the manifestations of the disorder may extend from organ-specific to systemic ones, including xerostomia, dry eyes, arthralgias/arthritis, rash, keratoconjunctivitis sicca, primary liver cirrhosis, lymphoma and lung involvement (2,3). The disorder is also characterized by hypergammaglobulinemia and autoantibody production, mainly against the ribonucleoproteins SS-A/Ro and SS-B/La characteristic of SS and identified in the serum of the patients (4). The increased levels of various cytokines such as interferon (IFN)-γ, interleukin (IL)-6 and IL-10 found in patients with SS have suggested their notable role in the pathogenesis of the disease (5,6). SS has a complex pathogenesis, involving interacting genetic, epigenetic, hormonal and environmental factors. Furthermore, additional activators of the disease include specific viruses, such as Epstein-Barr virus, human T-lymphotropic virus, retroviruses and Coxsackie virus (7-9). No effective treatment for SS has been developed so far. Current medical treatments focus on the alleviation of the symptoms of the disease as well as the decrease of inflammatory events (10).

Endometriosis is an enigmatic, multifactorial disorder, representing one of the most common gynecological diseases affecting 3-10% of women in their reproductive years, and it can be a debilitating disease leading to poor quality of life (11). Despite the frequent occurrence, its etiology and pathogenesis are poorly understood and the exact cause is unknown (12-14). Multiple genetic and epigenetic factors, in combination with interacting environmental factors, including pollution agents and toxins, lead to the development of this condition (15). It is characterized by ectopic localization of endometrial cells and, therefore, the occurrence of endometrial tissue outside the uterine cavity on other organs (16,17). Endometriosis can appear as ovarian endometriotic cysts, peritoneal lesions, fibrosis and deeply infiltrative endometriosis (15). It is associated with chronic pelvic pain, dysmenorrhea, irregular menstrual bleeding, deep dyspareunia and urinary tract symptoms, while ~30% of patients with endometriosis also suffer from infertility (18-20). Considering that all endometriosis cases cannot be explained by a uniform theory, apart from the favorable and most accepted theory of Sampson (21) based on retrograde menstruation hypothesis, more pathways and cellular processes have been considered, including angiogenesis, chronic inflammation, increased oxidative stress and endothelial dysfunction (22,23). Clinical presentation varies widely, ranging from asymptomatic to severe, and no diagnostic biomarkers have been approved for routine clinical diagnosis of endometriosis (24). Notably, the type and severity of symptoms depend on the extent of the disease and the location of the involved organ(s).

Advances in the past years have shown that female patients with endometriosis are at higher risk of developing chronic diseases as systemic comorbidities, such as cancer (25), cardiovascular diseases (26,27), asthma (25), hypothyroidism (25) and psychiatric disorders (28). Most importantly, epidemiological studies demonstrated that patients with endometriosis were associated with an increased risk of developing a number of autoimmune diseases compared with unaffected controls due to notable changes in immune-related parameters. The autoimmune diseases included in this category include rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's disease, coeliac disease, ankylosing spondylitis and autoimmune thyroid disorder (29-33). However, it is unclear whether autoimmune diseases represent a risk factor of endometriosis, or these two types of diseases share similar pathogenetic mediators.

Previous and recent epidemiological studies have suggested that endometriosis can increase the susceptibility to SS in these females compared with unaffected controls (29,34-36). Although the pathogenesis of SS has not been elucidated, there has been strong evidence pointing out the important role of genetics in the development of this disease. Moreover, current research has demonstrated substantial deregulation of the immune system of female patients with endometriosis and epidemiological studies have presented evidence for a link between endometriosis and an increased risk of developing SS (29,34-36). The etiology of this co-occurrence remains poorly defined. It is possible that the immunological alterations and chronic inflammation characterizing endometriosis may lead to SS. These similarities between molecular and cellular pathways of endometriosis and SS may implicate a partially shared genetic background. Thus, in the current review, an overview of the shared genetic factors known thus far that are associated with an increased susceptibility for both disorders are presented, while the review did not focus on the plausible clinical basis and relevant aspects regarding the co-occurrence of both diseases.

Endometriosis is a highly complex disease with numerous genetic, epigenetic and environmental factors interacting with each other, thus contributing to its pathogenesis (15). The identification and functional analysis of the numerous genetic factors involved in the development of endometriosis have notably contributed to the better understanding of the biological processes and molecular mechanisms leading to the disease, as presented in detail in recent studies by our research group (27,30,32). In brief, the strong genetic predisposition of the disease was documented firstly in monozygotic twin-based and family studies (37,38), followed by linkage analysis, various candidate and gene association, genome wide association studies (GWAS), meta-analyses and next-generation sequencing studies (39-53). As a consequence, a number of disease-associated gene polymorphisms have been detected, which are involved in estrogen-induced cell growth (WNT4 rs7521902), vascular function (KDR rs17773813), cell adhesion (VEZT rs10859871, KAZN rs10928050), growth and migration (FN1 rs1250241), matrix remodeling and angiogenesis (VEGF rs699947, LAMA5 rs2427284), cell cycle regulation (FAS rs1341643), transcription (ID4 rs7739264, MLLT10 rs1802669), differentiation (GDAP1 rs554964149), proliferation (MUC4 rs882605), oncogenesis (TP53 rs1042522, CHD5 rs9434741), inflammation (COX-2 rs20417), sex steroid hormone activity and metabolism (GREB1 rs13394619, FSHB rs74485684, SYNE1 rs71575922, CCDC170 rs1971256, ESR1 rs2206949), immunity (STAT4 rs7574865, IL-1A rs6542095, IL-10 rs1800871, IL-16 rs4072111) and oxidative stress (HIF-1α rs11549465) (41,42,46,47,52,53). Furthermore, accumulating evidence suggests that epigenetic aberrations seem to play an important role in the pathophysiology of endometriosis (54) and the development of some specific complications such as pain and infertility (11,55). The levels of DNA methylation, histone modifications and microRNA (miR/miRNA) expression reflect the main epigenetic information at the cellular level (56,57). These epigenetic changes may have potential applications in disease diagnosis, prognosis and therapeutic interventions (58). The importance of epigenetic modifications regarding numerous biological processes has been so far demonstrated according to findings from aberrant methylation studies as well as epigenome-wide association studies (EWAS) (59,60).

SS is a complex autoimmune disease with a number of well-established susceptibility loci. Worldwide studies focused on the detection of SS-associated alleles of human leukocyte antigen (HLA) genes, which encode cell surface antigen presenting proteins. Before the era of GWAS, associations between HLA genes and SS were detected concerning HLA-Dw3, HLA-B8, HLA-DRw3, HLA-DR3, DRw52 and HLA-B8 20 (61), while more recent studies focused on HLA identified DRw53 (62), DR2 (63), HLA-DRB1*01:01, HLA-B*35:01 (64), HLA-DQA1*050 (65), HLA-DRB1*0301 (66), HLA-Cw7, HLA-DR3 and HLA-DR11 (67). Other genetic studies of SS had been focused on familial aggregation (68). The first GWAS performed focusing on SS (69) detected six non-HLA loci, namely IFN regulatory factor 5 (IRF5)-TNPO3, signal transducer and activator of transcription-4 (STAT4), IL12A, FAM167A-BLK, CXCR5 and TNIP1, while previously reported HLA associations (61-67) were confirmed (69). Other GWAS established new associations with GTF2IRD1-GTF2I and tumour necrosis factor (TNF)AIP3 (70) as well as IRF5 (71). Other studies showed association of SS with TNF-α and IL-10 (72), OAS1 (73) and IKZF1 (74). In the most recent GWAS conducted by Khatri et al (75) on patients of European ancestry, 10 novel genome-wide marked SS-associated loci were identified, including CD247, NAB1, PTTG1-MIR146A, PRDM1-ATG5, TNFAIP3, X Kell blood group complex subunit-related family member 6 (XKR6), MAPT-CRHR1, RPTOR-CHMP6-BAIAP6, tyrosine kinase 2 (TYK2) and SYNGR1, while a subsequent meta-analysis based on ImmunoChip-derived data revealed three additional SS-loci, CD247, PRDM1-ATG5 and TNFAIP3 (75). It is worth noting that the SS susceptibility loci identified by Khatri et al (75) are implicated in alterations in immune cell function, inflammatory signaling, and cell stress, survival and proliferation. Regarding the epigenetic studies in SS, it was reported that in type I IFN-regulated genes, which were upregulated in the blood and salivary glands (SGs) of patients with SS (76,77), DNA hypomethylation was observed (77). Previous studies assessed global DNA methylation levels and specific CpG sites in various candidate genes, such as LTA as well as type I IFN-induced genes, including STAT1, IFI44L, MX1, IFI44L, PARP9 and IFITM1 (68). Furthermore, numerous large-scale EWAS managed to identify genetic regions exhibiting a differential DNA methylation pattern between patients with SS and healthy controls, including IRF5 promoter regions, TNFSF7 promoter, FOXP3, KRT19 and DNMT1 genes as well as LINE-1 (68,69).

Immune dysregulation leading to chronic inflammatory response in the ectopic endometrium aggravates a number of abnormalities in the cell-mediated as well as the humoral immune systems of patients (30). Furthermore, other studies suggested the association of endometriosis with both antibody self-reactivity and chronic local inflammation (11,23,27,30), caused by a variety of inflammatory factors such as cytokines, macrophages and prostaglandins, thus characterizing this disorder as an autoimmune one (74). In this framework, extensive research has been conducted to understand the influence of autoimmunity in endometriosis, aiming to gain better insight of the pathogenetic mechanisms leading to this condition (30). The identification of antibodies against endometrial antigens and the subsequent detection of anti-nuclear and anti-phospholipid antibodies in the blood and the peritoneal fluid (PF) of patients in combination with elevated levels of inflammatory cytokines, such as IL-6, IL-8 and TNF-α, supported pre-existing data indicating a critical role of autoimmunity in endometriosis (78). This role was further strengthened by the loss of self-tolerance, leading to immune-mediated tissue destruction and multi-organ involvement, which represent immunological alterations also occurring in endometriosis (77). Furthermore, natural killer (NK) cells were found to be decreased in local NK-mediated cytotoxicity in the peripheral blood and PF of female patients with endometriosis (79), with this decrease being more pronounced in patients with endometriosis at stages II and IV as demonstrated by a notable reduction in NK activity (79). It has been suggested that inhibitory factors developing during the pathogenesis of endometriosis may suppress NK cell function (79). Abnormalities regarding the function and concentration of B- and T-lymphocytes as well as the total number of macrophages have also been observed in patients (77,80). Dysregulation of the immune system may prevent the ability to eliminate the endometrium of the pelvic cavity, while macrophages and NK cells (78) may be unable to destroy cells in ectopic sites (77). The hormonal alterations observed in endometriosis, such as higher levels of estradiol and progesterone (15,17), have been related to the inflammatory imbalance that is characteristic of this disorder, given that inflammation affects hormonal regulation (81). The strong association of endometriosis with inflammation has also been indicated by the elevated levels of the inflammatory cytokines IL-6, IL-10 and TNF-α (82) observed in the PF and peripheral blood of patients (83) (Fig 1).

As it was aforementioned, SS is a systemic, inflammatory, autoimmune disease characterized by exocrine dysfunction due to immunologically-mediated mechanisms (84). It follows the classical, multistep model of human autoimmune diseases. However, the immunological mechanisms that mediate the self-directed destruction of SG tissue are still not well understood. A periductal mononuclear cell infiltration has been found, leading to the collection of distinct cellular aggregates in SGs and lachrymal glands, and the subsequent chronic inflammation with signs in various organs including lungs, liver and kidneys (85). Moreover, it has been reported that the observed chronic inflammation is caused by an imbalance of cytokine production locally in the glands and systemically in the blood (86). The dysregulation of cytokines refers to alterations of both local and systemic expression of pro and anti-inflammatory cytokines released by infiltrating cells in inflamed tissues (87). A notable research finding refers to functional differences between the glandular and the peripheral blood lymphocytes, thus suggesting the existence of a distinct microenvironment in the gland compared with that in the peripheral blood, while the putative disruption of the T helper (Th) 1 and 2 cell balance cannot be underestimated (88). Notably, the aforementioned studies have also suggested a differential role for the action of Th1 and Th2 cytokines in SS (85,86,88); The Th1 cytokines IL-10, IL-6 and TGF-β are critical for the induction of SS, but Th2 cytokines, such as IL-4 and IL-5, may be related to the disease progression (89). It is noteworthy that IL-6 functions as a key player regarding B-cell differentiation and the production of autoantibodies. IL-6 is found at higher levels in patients with SS compared with healthy controls, thus contributing to the characteristic inflammatory state of the disorder (90). Moreover, it was recently reported that the proinflammatory cytokine IL-17, produced mainly by Th17 cells, is upregulated in SS as shown in numerous studies, thus being involved in the development of SS and, in particular, associated with the degree of inflammation and clinical manifestations (91-93). TNF-α and TNF-α-receptors also appear to be dysregulated in peripheral blood and secreting cells from SGs from patients with SS (94,95). Mackay and Tangye (96) have emphasized the role of the B cell activating factor (BAFF), which is a protein member of the TNF family produced by monocytes, T and dendritic cells (DCs). This protein is upregulated in SS and is associated with autoantibody production and B-cell tolerance (97). Numerous pathways that are strongly associated with IFN signaling were found to be upregulated in patients with SS, especially in SGs and plasmacytoid DCs (98). TGF-β, a cytokine crucial in Th17 polarization (93), is linked to the growth of regulatory T cells which are upregulated in inflamed SGs of patients with SS (98). It is noteworthy that accumulating evidence document that a broad spectrum of impaired immune functions results in the pathogenesis of SS, including the cytotoxic cellular cytokines IL-1β, IL-12p40, IL-15 and TNF-α, the humoral cytokine IL-6, and the factors and death receptors TNF-RI and TNF-RII (99,100).

Although the etiology of endometriosis is highly complex and far from being fully elucidated, there is compelling evidence attributing a critical role in angiogenesis and lymphangiogenesis, which are involved in both the invasion to the extracellular matrix and ectopic implantation of endometrial tissue, and the development of endometriotic lesions (101). Angiogenesis confers to the maintenance of the endometriotic lesions by supplying them with functional blood vessels and, as a consequence, leading to the formation of a dense vascularization (102). The angiogenic properties of the endometrium and its strong potential to attract blood vessels from the surrounding tissue is well established (103). Moreover, various potent angiogenic factors such as TGF-α, TGF-β, basic fibroblast growth factor and angiopoietin (32) have been found to be altered in endometriosis, thus suggesting the involvement of angiogenesis in the ectopic implantation of the endometrial cells (104). A number of genetic polymorphisms of key components of the angiogenesis mechanism, including placental growth factor rs2268614, hypoxia inducible factor-1α (HIF-1a) rs11549465 and vascular endothelial growth factor (VEGF) receptor 1 (VEGFR1) rs9582036, were found to be associated with the development of endometriosis. Thus, it has been demonstrated that all these single nucleotide polymorphisms (SNPs) contribute to the variability in the plasma levels of the encoded proteins (105,106). In the same framework, data have shown that higher expression levels of VEGF and angiopoietin-1 led to dysregulated angiogenic activity of the utopic endometrium in patients with endometriosis (101,107). It is known that VEGF activates the migration of various inflammatory cells, including monocytes and lymphocytes, into the extracellular matrix (108). It is noteworthy that another study showed that predominantly in adolescent and young adult female patients with endometriosis, increased levels and marked activation of circulating proteins related to angiogenesis and cell migration were observed (109). The further identification of new factors associated with angiogenesis may be important for developing novel therapeutic approaches for endometriosis.

Marked discoveries regarding the molecular mechanisms leading to SS have highlighted the role of angiogenesis (110), a fundamental process in growth and development (111). Previous experiments have shown that the metalloproteinase TNF-α-converting enzyme, which participates in proangiogenic pathways leading to the formation of vessels (112,113), is involved in VEGF/VEGFR2-mediated angiogenesis in SS (114). Furthermore, it has been shown that infiltrating T-cells, in combination with human SG epithelial cells (SGECs), produce increased amounts of proangiogenic factors through the activation of the VEGF-A/VEGFR-2 system (115). Various findings have shown that a proangiogenic protein, the metalloproteinase TNF-α-converting enzyme (TACE) is overproduced in SS, thus emphasizing the role of the VEGF-A/TACE/VEGFR2/NF-κB axis dysfunction in the pathogenesis of SS (114). In the same framework, neuropilin, which represents a transmembrane co-receptor of the VEGF protein family members, was reported to promote angiogenesis in SS by activating NF-κB (116). Moreover, quantification and characterization of circulating angiogenic T (Tang) cells in minor SGs (MSGs) and in the peripheral blood of patients with SS showed that this type of cells may participate in endothelial dysfunction and glandular angiogenesis observed in SS (117). Importantly, Tang cells infiltrate MSGs and are directly associated with disease activity in patients with SS (117).

miRNAs are naturally-occurring, small (~22 nucleotides in length), non-coding, post-transcriptional regulatory molecules, expressed in a tissue-specific and cell-type-specific manner, targeting numerous mRNAs (196,197). miRNAs represent an evolutionary system that regulates numerous biological processes such as embryonic development, cell cycle, migration and proliferation, differentiation, immune responses as well as apoptosis (198,199), while also being implicated in the development of various autoimmune diseases including SLE, RA, MS, AS, SS, experimental autoimmune encephalomyelitis, type 1 diabetes mellitus, inflammatory bowel disease, psoriasis, primary biliary cirrhosis and idiopathic thrombocytopenic purpura (199-201). To date, various studies have demonstrated an aberrant expression of miRNAs in affected tissues or blood serum samples of patients with endometriosis (56,57,202). Moreover, the critical role of miRNAs has been documented in SS with regards to the post-transcriptional mRNA expression on PBMCs and SGs (203). Thus, several studies have investigated the participation and contribution of miRNAs in endometriosis as well as SS etiopathogenesis (204,205). Notably, various miRNAs have been reported to have a similar expression profile in both diseases, including miR16 (203,206-210), miR18a-5p (203,211,212), miR19b-3p (208,213-215), miR26a-5p (208,209,213), miR30c-5p (59,208,209), miR122-3p (214,216), miR142 (217,218), miR146a-5p (217,219,220), miR155-5p (218,221), miR181a (222-225), miR200b (220,226), miR223-3p (203,213) and miR378a-3p (213,227) (Table II).

miR16 was found to be upregulated in the plasma of patients with endometriosis compared with controls (206) as well in the saliva of patients with SS (207). This miRNA is considered a potential diagnostic biomarker for endometriosis (228). Furthermore, it was shown that there is an association between miR16 and autoantibodies against both Ro/SSA (SSA) and La/SSB (SSB) in labial SG tissues of patients with SS (205).

miR17-5p was reported to be downregulated in the serum and blood of female patients with endometriosis (162,208) as well as in the saliva of patients with SS (203,210). Investigation of the expression of this miRNA led to its use as a non-invasive diagnostic marker of endometriosis (162). The observed downregulation of miR17-5p results in the upregulation of the targets BCL2 and cell cycle repressor cyclin-dependent kinase inhibitor 1A repressing cell proliferation (229). Furthermore, the downregulation of miR17-5p is involved in neo-angiogenesis, through its association with HIF-1α (230) as well as VEGF-A (231). Notably, the miRNA under discussion exhibits a notable inverse association with thrombospondin 1 levels, a protein that modulates cell migration and adhesion (232).

miR18a-5p has been found to be upregulated in the serum of patients with stage III and IV endometriosis compared with control subjects (211), and in the SGs of patients with SS (203,212). It has been previously reported that this serum miRNA is considered a diagnostic marker of endometriosis (211).

miR19b-3p is downregulated in the blood of patients with endometriosis compared with controls (208) and in B-lymphocytes of patients with SS (213). This miRNA is a member of a miRNA cluster that plays a pivotal role in cell proliferation and apoptosis but is often deregulated in immune-associated diseases (233). Moreover, decrease in miR19b-3p levels was associated with accumulation of mature B cells that have been linked to autoimmune diseases including SS (210,234).

miR21-3p was found to be upregulated in ectopic endometrium of female patients with severe endometriosis compared with control subjects (214) as well as in patients with SS (215). This miRNA was previously shown to be associated with endometrial receptivity as well (235), while it has been reported to be regulated by oxidative stress (236). Thus, this miRNA participates in the oxidative stress- and immune-related AKT pathway, by targeting the inhibitory molecule PTEN (237), while it also targets PDCD4, E2F1 and TGFBRII (238).

miR26a-5p was found to be downregulated in the blood of patients with endometriosis compare with controls (208), and in B-lymphocytes of patients with SS (213).

miR30c-5p was shown to be downregulated in the serum of patients with endometriosis compared with controls (208,209), and in the saliva of patients with SS (59,203). Furthermore, downregulation of this miRNA by targeting PAI-1 was shown to increase the invasion, migration and proliferation of human embryonic stem cells, thus pointing out the role of miR30c-5p in endometriosis (215). Functional experiments showed that the expression of miR30b-5p in B cells from patients with SS was inversely associated with the expression of the BAFF gene (209). Furthermore, this miRNA was found to play a role as a negative regulator of BAFF in both systemic sclerosis and RA fibroblasts (239). miR30b-5p was also found to be notably deregulated in the B cells of patients with SS (209). Thus, miR30b-5p was found to be 3.5 times more downregulated in B cells of seropositive (anti-SSA⁺) patients with pSS compared with control subjects, than B cells from seronegative (anti-SSA) patients with SS (209).

miR122-3p is upregulated in the serum and PF of patients with endometriosis compared with controls (213,240); similarly, the same miRNA was found to be upregulated in PBMCs from patients with SS (215). The diagnostic power of this miRNA has been assessed in endometriosis, and it was shown that serum miR122-3p had a sensitivity of 95.6 and a specificity of 91.4 for the diagnosis of the status of the disease (216). Thus, this miRNA can be considered as a putative serum biomarker for endometriosis (216).

miR142 was found to be upregulated in the utopic endometrium of patients with endometriosis compared with controls (228), while it was also found to be upregulated in the saliva and SGs of patients with SS (218). This miRNA regulates autophagy mediated by KLF9 and, therefore, may suppress endometriosis (35).

miR146a is upregulated in the utopic endometrium of patients with endometriosis compared with controls (217), and is also upregulated in the PBMCs of patients with SS (218,220). It represents an excellent example of a master regulator as it contributes to numerous aspects of immunity, including the control of cytokine overproduction, the suppression of regulatory T (Treg) cells and the control of TLR signaling in recurrent bacterial infection (241-243). This miRNA can also modulate cell death processes and, therefore, it can act as an antiapoptotic factor in T cells (244). Moreover, miR146a is activated by NF-kB that plays a crucial role in controlling the TLR/IFN pathway (245). In this framework, the elevated expression of miR146a found in PBMCs from patients with SS (220) is of high importance given that it regulates the inflammatory response (negative regulator) by controlling properly the expression of IRAK1 and TRAF6 genes (246). Furthermore, elevated miR146a levels have been associated with an increased percentage of Th17 cells in patients with SS compared with healthy subjects (247). All aforementioned data suggest that abnormal regulation of miR146a is involved in early disease pathogenesis and progression.

miR155-5p was found to be downregulated in the plasma of patients with endometriosis compared with control subjects (221) and in PBMCs of patients with SS compared with controls (219). This miRNA is considered a key modulator regarding both the innate and adaptive immune response, activated by NF-kB, which is known to control the TLR/IFN pathway (245), while it further regulates the proliferation and function of B and T cells (248). miR155-5p is also involved in the regulation of immune cells, particularly in SS (220).

miR181a is upregulated in the blood of patients with endometriosis compared with controls (222) as well as in the SGECs and PBMCs of patients with SS (223-225). The levels of miR181a in PBMCs of patients with SS have been associated with exocrine gland dysfunction and antigen sensitivity (225), while additional data have shown that miR181a targets the muscarinic receptor 3 gene, which harbors genetic variants that are markedly associated with SS (249,250). The increased levels of miR181a have been associated with the degree of inflammation observed the patients with SS (209).

miR200b is upregulated in the ectopic endometrium of patients with endometriosis compared with the utopic endometrium of controls (226). This miRNA is also upregulated in SS (220). Regarding endometriosis, it has been suggested that the regulation of miR200b may modulate the proliferation and differentiation of stem cells (251). miR-200b targets the ZEB1, ZEB2 and KLF4 genes, thus affecting the proliferation and invasiveness of endometriotic cells (251). Furthermore, it participates in the regulation of various target genes involved in epithelial-mesenchymal transition and angiogenesis (252), thus contributing to the pathogenesis of endometriosis (253).

miR223-3p is upregulated in the ectopic endometrium of patients with endometriosis compared with the utopic endometrium of control subjects (214). Similarly, it is upregulated in PBMCs and saliva of patients with SS (203,254). The miR223 gene is located within the q12 locus of the X chromosome and its product was also found at high levels in vascular smooth muscle cells (255). It has been assumed to play a role in endometriosis considering its well documented involvement in cell proliferation, migration as well as in vascular remodeling and apoptosis (256). The role of miR223-3p in SS is still unclear. However, it was also found to be upregulated in CD4⁺ naïve T lymphocytes from patients with RA patients, suggesting a possible role of this miRNA in disease pathogenesis (257). This miRNA has been characterized as an inflammation-related one but it has also been linked to oxidative stress regulation (258). A study focused on a neuronal model treated with H₂O₂, overexpression of miR223 reduced malondialdehyde and reactive oxygen species levels, a finding that could be explained by the effect of this miRNA that targets FOXO3a and leads to the inhibition of thioredoxin interacting protein (258).

miR378a-3p is downregulated in the plasma of patients with endometriosis compared with controls (227), and in B-lymphocytes of patients with SS (213).

The present review is a first attempt at searching the literature and analyzing the genetic and epigenetic factors that are involved in the co-occurrence of endometriosis and SS, aiming to shed a light in some shared mechanisms involved in both conditions while also pointing to the delineation of the relevant biochemical and molecular pathways. In the present review, the clinical basis underlying the co-occurrence of both diseases was not investigated. As presented already in the current review, the influence of autoimmunity, inflammation, tissue remodeling and angiogenesis in the underlying biochemical, cellular and pathophysiological mechanisms leading to the reported association between endometriosis and SS has been documented. Although it was beyond the scope of the present review to discuss all these processes in detail, some aspects regarding their role in the development of SS and endometriosis were clearly shown in previous sections. The role of autoimmunity in endometriosis has been hypothesized and/or established considering that a series of anti-nuclear, anti-phospholipid and anti-endometrial antibodies are present in this condition, in combination with elevated levels of inflammatory cytokines and various immune cell-mediated abnormalities (74,78). Aiming to unravel the aforementioned mechanisms, different explanations can be given, including the putative role of chronic inflammation and immune dysregulation appearing in endometriosis when it co-occurs with SS. The development of ectopic endometrial cells and lesions may provoke an increased immune response, which may be combined with pathological causes leading to SS. Furthermore, the hypothesis that endometriosis should be considered an autoimmune disease has been strengthened by the beneficial effects of danazol and GnRH agonists as part of endometriosis treatment, likely due to their immunomodulatory action (259) as well as the increased number of peritoneal macrophages, high T and B lymphocyte counts (260) and the increased levels of circulating anti-endometrial antibodies (261). However, the putative mechanisms leading to endometriosis in female patients with SS remain largely uncertain, given that studies from different countries examining this relationship have not yet reached a consensus. Together, the possible role of SS in the etiology of endometriosis or the occurrence of SS as a secondary response to endometriosis needs further exploration from a genetic and biological aspect (36).

It is known that understanding the genetic basis of complex diseases may provide a unique window into human disease pathogenesis, which will facilitate the development of improved diagnostic and therapeutic strategies and enable personalized medicine. However, apart from the substantial contribution of various GWAS to the identification of a number of SNPs associated with an increased risk of endometriosis or SS development, only a small number of these associations have been analyzed in depth from a functional aspect, thus minimizing the potential of these SNPs to be considered as putative therapeutic targets. Therefore, despite the efforts to analyze the biochemical pathways leading to endometriosis, it remains an emerging public health problem of reproductive-age women and the pathogenesis remains elusive. It has been reported that the prevalence rate of endometriosis in women with chronic pelvic pain is >33%, and in patients with SS the prevalence rate is 6.3% (262). In the same study (262), it was reported that patients with endometriosis were more likely to also have SS compared with controls (262). The risk of endometriosis has been strongly linked to ethnicity but the main differences between population groups have not been well defined (263). A nine-fold increase in the risk of developing endometriosis among females from the East Asian population was found compared with European or American female populations (263). It is noteworthy that various studies are currently trying to delineate how disease risk variation is linked to ethnicity, and to identify minor differences in SNP variation and differences in autoimmune disease risk variants reported across different continental populations (263). The worldwide range of prevalence of SS is 0.05-4.8% with an overall 9:1 female-to-male ratio, which appears highest in Asian females (36). However, a limitation of this type of studies is the lack of information on the patient's socioeconomic status, personal health behaviors or toxic habits, with all of them representing confounding factors of the association between endometriosis and SS (36).

Taking into account that endometriosis has been associated with various autoimmune diseases, this condition may be considered a risk factor for SS, which requires specific counseling and medical management. Immune and inflammatory dysfunctions are considered challenging therapeutic targets for endometriosis and SS. The ultimate task of this type of study is the development of either novel therapeutic alternative by using the in depth understanding of the role of the associated shared genetic factors or the use of some miRNAs, a class of agents considered possible immunomodulators, considering that miRNAs exhibiting a deregulation in both endometriosis and SS have been identified. Thus, translation of recent discoveries based on miRNAs may allow the development of novel therapeutics for endometriosis and SS in the near future, considering that it has been shown that this type of drugs provide specificity and reduced toxicity compared with other therapeutic agents (264,265). The human miRNAome has been recently analyzed to define a saliva-based diagnostic miRNA signature for patients with endometriosis, based on their expression profile, and the results of this study may contribute to the early diagnosis of this condition (266).

The treatment of complex diseases has undergone substantial change over the last few years and novel, promising therapies have been developed. As presented in the current review, two SNPs of the STAT4 gene, a member of the JAK/STAT pathway playing a pivotal role in IFN signaling related to immunological processes promoting chronic inflammation, are associated with both endometriosis and SS. As a consequence, a promising therapeutic option may be JAK inhibitors that interrupt the transduction of the aforementioned JAK/STAT pathway (267,268). Accumulated results suggest that the JAK inhibitor tofacitinib, a signal transducer associated with inflammation, can be used as an anti-inflammatory agent in patients with SS (269). The JAK/STAT pathway, especially STAT3 phosphorylation, is upregulated in the utopic endometrium of female patients with endometriosis (270), and it has been reported that inhibition of JAK/STAT signaling using tofacitinib may be a viable method for the treatment of endometriosis as well (271). One of the genes that are activated by STAT3 is HIF1α, which is associated with both diseases (64,127).

The SNP rs1800629 of the TNF-α gene is associated with both endometriosis and SS (Table I). The targeting of the inflammatory cytokine TNF-α expressed at high levels in the peripheral blood or tissue of patients with SS (126,181) may represent another beneficial therapeutic option for a large percentage of affected patients. In this context, it has already been shown that TNF-α also stimulates proliferation of endometriotic stromal cells, thus playing the role of an essential factor for the pathogenesis of endometriosis (272). This cytokine was found at high levels in female patients with endometriosis (273). Etanercept, a TNF-α blocker that can neutralize the activity of TNF and is currently used to alleviate the symptoms of autoimmune diseases clinically (274), has been shown to block the ability of the PF in endometriosis to enhance the proliferation of utopic or ectopic endometrial cells (275). However, the efficacy of etanercept in the treatment of SS has not been addressed. When it was used for a prolonged treatment of patients with SS, it did not appear to reduce the main symptoms of the patients, being beneficial in a small subgroup of patients with severe fatigue only (276), while Sankar et al (277) did not find any evidence suggesting that treatment with etanercept is clinically efficient in patients with SS (277). Consistently, Moutsopoulos et al (278) also presented data indicating that etanercept is an ineffective therapeutic agent in SS, thus suggesting that TNF-α may not be a pivotal cytokine in the pathogenesis of SS (278). In addition, infliximab, another anti-TNF-α agent, failed to demonstrate any beneficial effect in SS (279) and endometriosis (280).

Clinicians should always keep in mind that patients with endometriosis may also have additional autoimmune diseases, including SS, while the possible co-occurrence of endometriosis in patients with SS should not be underestimated. Thus, female patients with endometriosis, apart from their reference for follow-up with the gynecologist have to be alerted if they have any symptoms characterizing SS, such as xerophthalmia, xerostomia, fatigue, vaginal dryness, myalgia or arthralgia, and report it immediately to the rheumatologist. It has been reported that female patients with endometriosis have a higher risk of developing SS within the first 5 years (36). Thus, a suitable medication must be provided to these female patients by clinicians. In this framework, Bardi et al (281) presented the new concept of 'holism' for endometriosis, which leads physicians to evaluate this disorder in a complex and global way, considering its increased risk to co-occur with various autoimmune diseases. This combined, global approach is expected to result in beneficial patient management, taking into account the heterogeneous character of these diseases. In conclusion, information that can be derived by analyzing the intersection between autoimmunity, inflammation and angiogenesis, and the identified shared genetic factors may be of high value in understanding the underlying biochemical and cellular mechanisms of the association between endometriosis and SS, thus contributing to the development of novel therapeutic alternatives for both disorders.